Metastatic Solid Neoplasm (DBCOND0080723)

Identifiers

Synonyms
Solid Metastatic Tumor / Metastatic Solid Tumors / Metastatic Solid Tumor

Associated Data

Indicated Drugs and Targets
DrugDescriptionTargets
Entrectinib
Entrectinib is indicated for the treatment of metastatic ROS1-positive non-small cell lung cancer in adults. Entrectinib is also indicated in adults and children over 12 years old for the treatment...
Larotrectinib
A kinase inhibitor used to treat solid tumors with neurotrophic receptor tyrosine kinase gene fusion, are metastatic, high risk for surgery, or have no alternative treatments.
Repotrectinib
A tyrosine kinase inhibitor used to treat locally active or metastatic non-small cell lung cancer
Selpercatinib
A RET receptor tyrosine kinase inhibitor for the treatment of RET-driven non-small cell lung cancer, medullary thyroid cancer, and thyroid cancer in appropriate patient populations.
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT06657144
A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumorstreatment1not_yet_recruiting
NCT04585750
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)treatment1 / 2recruiting
NCT04761198
A Study of Etigilimab and Nivolumab in Subjects With Locally Advanced or Metastatic Tumors.basic_science1 / 2completed
NCT04799054
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumorstreatment1 / 2active_not_recruiting
NCT05639751
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutationtreatment1recruiting
NCT05828303
A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumorstreatment1not_yet_recruiting
NCT05875168
First-in-Human Study of DS-3939a in Participants With Advanced Solid TumorsNo drug interventionstreatment1 / 2recruiting
NCT05898399
Study of ART6043 in Advanced/Metastatic Solid Tumors Patientstreatment1 / 2recruiting
NCT06238479
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsNo drug interventionstreatment1recruiting
NCT06244771
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid TumorsNo drug interventionstreatment1 / 2recruiting
NCT06253195
BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumorstreatment1recruiting
NCT06666270
Phase I Study of SYN818 Monotherapy in Patients with Locally Advanced or Metastatic Solid TumorsNo drug interventionstreatment1not_yet_recruiting
NCT06465069
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsNo drug interventionstreatment1recruiting
NCT06521554
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)No drug interventionstreatment1recruiting
NCT06560645
A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 MutationNo drug interventionstreatment1recruiting
NCT06561685
A Study of LY4050784 in Participants With Advanced or Metastatic Solid TumorsNo drug interventionstreatment1recruiting
NCT06607185
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumorstreatment1not_yet_recruiting
NCT04898543
QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumorstreatment1recruiting
NCT05081609
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignanciestreatment1 / 2recruiting
NCT05935098
A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumorstreatment1recruiting
NCT06108050
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumorstreatment1recruiting
NCT06630247
A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid TumorsNo drug interventionstreatment1recruiting
NCT04319198
Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziytreatment4enrolling_by_invitation
NCT05867121
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumorstreatment1recruiting
NCT06163391
A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic CancerNo drug interventionstreatment1recruiting
NCT06440005
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid TumorsNo drug interventionstreatment1recruiting
NCT05004116
A Study of Repotrectinib in Combination with Chemotherapy in Children and Young Adults with Solid Tumor Cancertreatment1 / 2recruiting
NCT05688280
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STSNo drug interventionstreatment1 / 2recruiting
NCT06427941
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab, in Participants With Advanced or Metastatic Solid Tumorstreatment1recruiting
NCT06540066
A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumorstreatment1recruiting
NCT04977453
GI-101 As a Single Agent or in Combination with Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumorstreatment1 / 2recruiting
NCT04986865
A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomastreatment1recruiting
NCT05673928
A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients with HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)treatment2recruiting
NCT05863052
Analyzing Clinical Outcomes and Genomic Data of American Indian Patient PopulationNo drug interventionsNot AvailableNot Availableactive_not_recruiting
NCT06235437
Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141No drug interventionstreatment1recruiting
NCT06587295
Intramuscular ACM-CpG Monotherapy in Patients With Advanced/Metastatic Solid Tumors With Prior Response to Immunotherapy Alone or in Combination With ChemotherapyNo drug interventionstreatment1not_yet_recruiting
NCT06590506
High Definition Medicine for Solid Tumors OncologyNo drug interventionsNot AvailableNot Availablerecruiting
NCT06302621
Pemigatinib + Afatinib in Advanced Refractory Solid Tumorstreatment1recruiting
NCT04393454
Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapytreatment2terminated
NCT04447651
Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)No drug interventionsNot AvailableNot Availableactive_not_recruiting
NCT05828277
A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patientstreatment1withdrawn
NCT05071183
A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumorstreatment1 / 2terminated
NCT05471271
IL-2 PET Imaging in Advanced Solid TumoursNo drug interventionsdiagnosticNot Availablerecruiting
NCT01393509
The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignanciestreatment1completed
NCT05694715
Combination Therapy in Cancers With Mutations in DNA Repair Genestreatment1recruiting
NCT05919537
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutationtreatment1recruiting
NCT04419532
A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid TumorsNo drug interventionstreatment1recruiting
NCT04137900
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignanciestreatment1recruiting
NCT04294875
Phase I, FIH, MTD for MPT0B640, Multi-centre, Open-label, Subject With Locally Advanced or Metastatic Solid Malignanciestreatment0withdrawn
NCT05824975
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 in Patients With Advanced Solid TumorsNo drug interventionstreatment1 / 2recruiting
NCT05769075
A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 AlterationsNo drug interventionstreatment1recruiting
NCT01390818
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumorstreatment1completed
NCT04914117
A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumourstreatment1completed
NCT04892017
A Phase 1/2 Study of DCC-3116 in Patients With RAS/MAPK Pathway Mutant Solid Tumorstreatment1 / 2recruiting
NCT05862324
TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)No drug interventionstreatment1 / 2recruiting
NCT03263416
Study Evaluating Treatment Adherence in Patients Treated With Oral Targeted Therapy in Oncology Supported by a Dedicated and Coordinated Follow-up Compared to Standard Follow-up.No drug interventionshealth_services_researchNot Availablecompleted
NCT04579757
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumorstreatment1 / 2active_not_recruiting
NCT05384626
A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)treatment1 / 2recruiting
NCT05268666
A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumorstreatment1 / 2recruiting
NCT05480865
SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutationtreatment1recruiting
NCT04849273
A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLCtreatment1terminated
NCT05631327
A JZP341 Study in Adult Participants With Advanced or Metastatic Solid TumorsNo drug interventionstreatment1terminated
NCT04161391
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or MutationsNo drug interventionstreatment1 / 2terminated
NCT00997529
Mini Allo Stem Cell Transplantation for the Treatment of Solid TumorsNo drug interventionstreatmentNot Availablecompleted
NCT05118789
A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)No drug interventionstreatment1 / 2recruiting
NCT04614740
The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid TumorsNo drug interventionstreatment1 / 2recruiting
NCT05872867
Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90)treatment1recruiting
NCT05837767
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft TissueNo drug interventionstreatmentNot Availablerecruiting
NCT00611468
Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumorstreatment1completed
NCT05678010
A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor CancerNo drug interventionstreatment1recruiting
NCT04383210
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumorstreatment2active_not_recruiting
NCT05983523
A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced or Metastatic Solid TumorsNo drug interventionstreatment1not_yet_recruiting
NCT05279690
Pilot Trial of Colchicine in Urothelial Cancer and Other Solid Tumorstreatment1recruiting
NCT04602702
Hyper-Personalized Medicine Using Patient Derived Xenografts (PDXovo) for Metastatic Solid TumorsNo drug interventionsNot AvailableNot Availableunknown_status
NCT03284502
HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumorstreatment1active_not_recruiting
NCT06415487
ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)treatment1not_yet_recruiting
NCT04471987
Safety and Early Signs of Efficacy of IL12-L19L19.No drug interventionstreatment1recruiting
NCT06577987
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor MalignanciesNo drug interventionstreatment1recruiting
NCT05126433
Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors (EMERGE-201)treatment2completed
NCT05028478
A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic MalignanciesNo drug interventionstreatment1 / 2unknown_status
NCT05232409
Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancertreatment1recruiting
NCT05259709
A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimabtreatment1recruiting
NCT04706715
LAG3 PET Imaging in Advanced Solid Tumorsother1 / 2active_not_recruiting
NCT05076552
A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic CancerNo drug interventionstreatment1active_not_recruiting
NCT05530200
PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.No drug interventionstreatment2not_yet_recruiting
NCT05474859
Subjects With Advanced or Metastatic Solid Tumor MalignanciesNo drug interventionstreatment1not_yet_recruiting
NCT04474470
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancertreatment1 / 2active_not_recruiting
NCT06545942
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumorstreatment1recruiting
NCT06266299
A Study of KK2269 in Adult Participants With Solid Tumorstreatment1recruiting
NCT06270706
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumorstreatment1recruiting
NCT05103358
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)treatment2active_not_recruiting
NCT02133625
A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumorstreatment1completed
NCT05717348
A Study of ES014 in Patients With Locally Advanced or Metastatic Solid TumoursNo drug interventionstreatment1recruiting
NCT05809557
EMR Chemotoxicity Risk Calculator To Decrease Chemotherapy ToxicityNo drug interventionspreventionNot Availablecompleted
NCT03964727
Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumorstreatment2active_not_recruiting
NCT04761744
A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancerstreatment2unknown_status
NCT06548672
A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic CancerNo drug interventionstreatment1recruiting
NCT05435768
PraG With RANKL Inhibitor for the Treatment of Advanced Multiple Metastatic Solid TumorsNot AvailableNot Availablenot_yet_recruiting
NCT05479812
Dose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumorstreatment1recruiting
NCT05385081
PREcision Medicine in Cancer in Odense, DenmarkNo drug interventionsdiagnosticNot Availableunknown_status
NCT05856981
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumorstreatment1recruiting
NCT04801095
A Phase I Study of WM-S1-030 in Patients With Advanced Solid TumorsNo drug interventionstreatment1recruiting
NCT06171750
Phase I Study of ANK-101 in Advanced Solid TumorsNo drug interventionstreatment1recruiting
NCT05490043
A Trial of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomastreatment1recruiting
NCT03809624
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancertreatment1terminated
NCT06660654
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)No drug interventionstreatment2not_yet_recruiting
NCT05836324
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsNo drug interventionstreatment1recruiting
NCT04094610
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterationstreatment1 / 2recruiting
NCT05853367
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)treatment1recruiting
NCT06031441
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumorstreatment1recruiting
NCT05487235
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumorstreatment1recruiting
NCT05605496
NP137 Clinical and Biological Activities Assessment in Patients with Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 ImmunotherapiesNo drug interventionstreatment2recruiting
NCT06585488
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants with Advanced or Metastatic Solid Tumors with KRAS Mutations or Amplificationtreatment1not_yet_recruiting
NCT06614751
A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR PathwayNo drug interventionstreatment1not_yet_recruiting
NCT01976143
A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safetytreatment1completed
NCT02045602
Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumorstreatment1completed
NCT02228811
A Study of DCC-2701 in Participants With Advanced Solid Tumorstreatment1terminated
NCT00148993
Allogeneic Tumor Cell Vaccination in Patients With Solid TumorsNo drug interventionsNot Available1 / 2withdrawn
NCT02235688
Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumorstreatment1completed
NCT03388632
Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancerstreatment1recruiting
NCT00149019
Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies.No drug interventionstreatment2withdrawn
NCT03093116
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangementstreatment1 / 2recruiting
NCT00159016
Role of Glivec in Patients With Tumor Cells Positive for C-kit or PDGFR; a Multi Center Study.treatment2withdrawn
NCT03427320
Imaging of Advanced Tumours Using [131]I-IAZANo drug interventionsother1 / 2withdrawn
NCT03993873
Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in METtreatment1 / 2active_not_recruiting
NCT00878423
Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumorsbasic_science1completed
NCT00827203
A Safety Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium in Patients With Solid TumorsNo drug interventionstreatment1suspended
NCT03523390
Phase I/Ib Multiple Ascending Dose Study in Chinatreatment1completed
NCT04695847
M1231 in Participants With Solid TumorsNo drug interventionstreatment1completed
NCT00793897
Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumorstreatment1completed
NCT03646071
A Study of RX108 in Patients With Locally Advanced or Metastatic Solid TumorsNo drug interventionstreatment1unknown_status
NCT04457778
First in Human Study of M6223treatment1completed
NCT00670488
Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002)treatment1completed
NCT02281409
Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumorstreatment1 / 2completed
NCT01928459
Phase 1b Trial of BGJ398/BYL719 in Solid Tumorstreatment1completed
NCT01449370
Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancertreatment1completed
NCT05494918
First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant TumorsNo drug interventionstreatment1recruiting
NCT01847118
A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid TumorsNo drug interventionstreatment1unknown_status
NCT01543763
Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumorstreatment1active_not_recruiting
NCT03403725
MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I StudyNo drug interventionstreatment1terminated
NCT03910530
A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumorstreatment1completed
NCT03854227
A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumorstreatment1terminated
NCT03573544
This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.treatment1 / 2terminated
NCT04010240
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK StudyNo drug interventionsNot AvailableNot Availablecompleted
NCT02097810
Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.treatment1completed
NCT03893955
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumorstreatment1active_not_recruiting
NCT03802123
⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumorsdiagnostic2completed
NCT03059823
A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumorstreatment1completed
NCT04134312
A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancertreatment1completed
NCT03087591
APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by SurgeryNo drug interventionstreatment1completed
NCT04167137
Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participantstreatment1terminated